Price Chart

Profile

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company’s other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
URL https://www.curevac.com
Investor Relations URL https://www.curevac.com/en/investor-relations/
HQ State/Province N/A
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Apr. 24, 2025 (est.)
Last Earnings Release Nov. 12, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company’s other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
URL https://www.curevac.com
Investor Relations URL https://www.curevac.com/en/investor-relations/
HQ State/Province N/A
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Apr. 24, 2025 (est.)
Last Earnings Release Nov. 12, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A